Rules-Based Medicine gets $25M, settles lawsuit

An Austin biotech firm received $25 million in funding for acquisitions, to purchase stock from its former parent company and to settle a lawsuit over licensing.Rules-Based Medicine Inc. will pay $12.5 million to Luminex Corp. (Nasdaq: LMNX) to settle the lawsuit, retire the public company's stock ownership in RBM and receive additional licensing rights.

California attorneys